⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ACAD News
Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
businesswire.com
ACAD
Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE ® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology
businesswire.com
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
ACAD